Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWIPE2
NCT05208242Phase 3Completed
- Sponsor
- Manchester University NHS Foundation Trust
- Start
- Nov 2023
- Primary completion
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of albumin (human) in septic shock (2 arms), sponsored by Manchester University NHS Foundation Trust. Primary endpoint: Participant recruitment rate at 24 months. Started Nov 2023; status: completed.
02
Drugs
albumin (human)
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT05208242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05208242.